These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 34113082)
1. Willingness-to-Pay and Benefit-Cost Analysis of Botulinum Toxin for the Treatment of Rosacea in China: Findings from a Web-Based Survey. Yang X; Ouyang Y; Deng Y; Xiao Y; Tang Y; Jian D; Li J; Xie H; Huang Y Patient Prefer Adherence; 2021; 15():1197-1205. PubMed ID: 34113082 [TBL] [Abstract][Full Text] [Related]
2. Willingness-to-Pay and Benefit-Cost Analysis of IPL for Rosacea Treatment: A Cross-Sectional Study in China. Deng Q; Zhang SP; Deng YX; Liu FF; Shi W; Xie HF; Xiao Y; Huang YX; Li J Patient Prefer Adherence; 2020; 14():1843-1852. PubMed ID: 33116428 [TBL] [Abstract][Full Text] [Related]
3. Health Related Quality of Life of Rosacea Patients in China Assessed by Dermatology Life Quality Index and Willingness to Pay. Huang Y; Yan S; Xie H; Wang B; Zhao Z; Huang Y; Li J Patient Prefer Adherence; 2022; 16():659-670. PubMed ID: 35283624 [TBL] [Abstract][Full Text] [Related]
4. Willingness-to-pay and benefit-cost analysis of chemical peels for acne treatment in China. Xiao Y; Chen L; Jing D; Deng Y; Chen X; Su J; Shen M Patient Prefer Adherence; 2019; 13():363-370. PubMed ID: 30863024 [TBL] [Abstract][Full Text] [Related]
5. Willingness to pay and quality of life in patients with rosacea. Beikert FC; Langenbruch AK; Radtke MA; Augustin M J Eur Acad Dermatol Venereol; 2013 Jun; 27(6):734-8. PubMed ID: 22583164 [TBL] [Abstract][Full Text] [Related]
6. Psychological Burden and Willingness to Pay Among Korean Rosacea Patients and Their Association With Rosacea Phenotype and Severity: A Multi-Center Cross-Sectional Study. Woo YR; Kim S; Cho SH; Kim HS J Cutan Med Surg; 2023 Nov; 27(6):601-607. PubMed ID: 37587799 [TBL] [Abstract][Full Text] [Related]
7. Botulinum Toxin A Alleviates Persistent Erythema and Flushing in Patients with Erythema Telangiectasia Rosacea. Yang R; Liu C; Liu W; Luo J; Cheng S; Mu X Dermatol Ther (Heidelb); 2022 Oct; 12(10):2285-2294. PubMed ID: 35925473 [TBL] [Abstract][Full Text] [Related]
8. Impacts of skin disorders associated with facial discoloration on quality of life: Novel insights explaining discordance between life quality scores and willingness to pay. Yang TT; Lan CE J Cosmet Dermatol; 2022 Jul; 21(7):3053-3058. PubMed ID: 34706154 [TBL] [Abstract][Full Text] [Related]
9. A randomized, controlled, split-face study of botulinum toxin and broadband light for the treatment of erythematotelangiectatic rosacea. Tong Y; Luo W; Gao Y; Liu L; Tang Q; Wa Q Dermatol Ther; 2022 May; 35(5):e15395. PubMed ID: 35187781 [TBL] [Abstract][Full Text] [Related]
10. Willingness to pay for contagious bovine pleuropneumonia vaccination in Narok South District of Kenya. Kairu-Wanyoike SW; Kaitibie S; Heffernan C; Taylor NM; Gitau GK; Kiara H; McKeever D Prev Vet Med; 2014 Aug; 115(3-4):130-42. PubMed ID: 24774477 [TBL] [Abstract][Full Text] [Related]
11. The toxic edge-A novel treatment for refractory erythema and flushing of rosacea. Friedman O; Koren A; Niv R; Mehrabi JN; Artzi O Lasers Surg Med; 2019 Apr; 51(4):325-331. PubMed ID: 30311683 [TBL] [Abstract][Full Text] [Related]
12. Examining Willingness-to-Pay and Zero Valuations for a Health Improvement with Logistic Regression. Mavrodi AG; Chatzopoulos SA; Aletras VH Inquiry; 2021; 58():469580211028102. PubMed ID: 34271848 [TBL] [Abstract][Full Text] [Related]
13. Comparing willingness-to-pay and time-trade-off as the measures of burden of psoriasis: A pooled analysis of community, hospital, and web-based samples in China. Shen M; Xiao H; Zhu W; Lu Y; Jing D; Kuang Y; Li M; Guan X; Sheng P; Su J; Chen X; Xiao Y J Dermatol; 2022 Nov; 49(11):1131-1138. PubMed ID: 35906766 [TBL] [Abstract][Full Text] [Related]
14. Willingness to pay for a QALY based on community member and patient preferences for temporary health states associated with herpes zoster. Lieu TA; Ray GT; Ortega-Sanchez IR; Kleinman K; Rusinak D; Prosser LA Pharmacoeconomics; 2009; 27(12):1005-16. PubMed ID: 19908925 [TBL] [Abstract][Full Text] [Related]
15. Willingness to pay and quality of life in patients with atopic dermatitis. Beikert FC; Langenbruch AK; Radtke MA; Kornek T; Purwins S; Augustin M Arch Dermatol Res; 2014 Apr; 306(3):279-86. PubMed ID: 23982630 [TBL] [Abstract][Full Text] [Related]
16. Assessment of Skin Physiology Change and Safety After Intradermal Injections With Botulinum Toxin: A Randomized, Double-Blind, Placebo-Controlled, Split-Face Pilot Study in Rosacea Patients With Facial Erythema. Kim MJ; Kim JH; Cheon HI; Hur MS; Han SH; Lee YW; Choe YB; Ahn KJ Dermatol Surg; 2019 Sep; 45(9):1155-1162. PubMed ID: 30730346 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of Botulinum Toxin A as an Optional Treatment for Atopic Dermatitis. Khattab FM J Clin Aesthet Dermatol; 2020 Jul; 13(7):32-35. PubMed ID: 32983334 [No Abstract] [Full Text] [Related]
18. Is combination therapy for malaria based on user-fees worthwhile and equitable to consumers? Assessment of costs and willingness to pay in Southeast Nigeria. Onwujekwe O; Uzochukwu B; Shu E; Ibeh C; Okonkwo P Acta Trop; 2004 Jul; 91(2):101-15. PubMed ID: 15234659 [TBL] [Abstract][Full Text] [Related]
19. How do patients prefer specialized clinical pharmacy service to other prevention of mother-to-child transmission of human immunodeficiency virus services? An evaluation of their willingness to pay and willingness to accept choices and ratios. Isah A; Adibe MO; Abba A; Dim OF; Ekwuofu AA; Ma'aji HU; Ukwe CV; Udeogaranya PO; Okonta MJ J Clin Pharm Ther; 2021 Dec; 46(6):1695-1705. PubMed ID: 34448210 [TBL] [Abstract][Full Text] [Related]
20. Evaluation on the cost-effective threshold of osteoporosis treatment on elderly women in China using discrete event simulation model. Ni W; Jiang Y Osteoporos Int; 2017 Feb; 28(2):529-538. PubMed ID: 27581955 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]